Replies to post #75648 on NorthWest Biotherapeutics Inc (NWBO)

[iwasadiver]

I read it entirely and he missed every single point, got it all wrong, and as usual spoke about stuff he didn't understand what so ever. I've put out several posts stating what was in the Presentation Slides and what their significance is. He misunderstood how they came up with expected survival for the top 30% of patients in the trial and didn't even bother trying to look at the referenced study by MD Anderson nor the Royal Marsden Hospital (RMH) prognostic score for phase I patients upon which the survival expectations were based. The expected survivals were for ONLY those 30%, and were done after looking at the data, and going back and putting in the variables for those particular patients, not for every patient in the cohort.

[Gralsburg]

Bullshit, NWBO will fly above $1 soon
I speculate, of course :-)

[Rkmatters]

He's a genius for pointing out how it might not have helped some of those patients? A total of 19 patients were in the study for 2 weeks of injections. That's it. This trial enrolled patients in late stage advanced disease. These same patients had failed prior therapy, 1-6 prior therapies. They had growing tumors. Immunotherapy is known to increase tumor size. And so it shouldn't come as a surprise that roughly 50% of patients tumor grew (to a total of 1 centimeter) to disqualify them from further treatment. The study was a safety. Had it been an efficacy study, perhaps the "size" growth thing wouldn't have mattered as much. For the company to focus mostly on patients that had 4 vaccine injections is not the wrong thing to do. It's the smart thing to do, as they have more data on those patients. The rest of the data is there for scrutiny. But he should at least acknowledge the facts. Majority of the Patients were in the study for 2-4 weeks. That's it. And the facts are, many of the terminally ill patients are still alive. Period.